GNLX:NASDAQ
Genelux Corp
US$Â 2,54
arrow_downward
-0,59%(-0,015) 1D
12 okt, 16:00:01 GMT-4 · USD
search
Alle symbolen
| Symbool | Prijs | Wijziging | Wijzigingspercentage |
|---|
insights_autoBelangrijkste inzichten voor GNLX genereren…
Openen
US$Â 2,59
Hoog
US$Â 2,59
Laag
US$Â 2,51
Beursw.
115,15Â mln.
Gem. vol.
260,79K
Volume
72,62K
52 wk hoog
US$Â 8,54
52 wk laag
US$Â 2,29
WPA
US$Â -0,87
Bèta
0,59
Uitstaande aandelen
45,24Â mln.
Aantal medewerkers
26
Openen
US$Â 2,59
Hoog
US$Â 2,59
Laag
US$Â 2,51
Beursw.
115,15Â mln.
Gem. vol.
260,79K
Volume
72,62K
52 wk hoog
US$Â 8,54
52 wk laag
US$Â 2,29
WPA
US$Â -0,87
Bèta
0,59
Uitstaande aandelen
45,24Â mln.
Aantal medewerkers
26
Nieuwsartikelen
Van webbronnen en nieuwspartners
www.dars.gov.et
·
1 maand geleden
GNLX Q2 2026 Earnings: Wider-than-Expected Loss Reflects Continued Clinical Investment - Earnings Yield Analysis
Profiel
Genelux Corporation is a publicly traded late clinical-stage company developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Over Genelux Corp
CEO-
Medewerkers26
Opgericht2001
HoofdkantoorWestlake Village, Californië, Verenigde Staten
Sector-
Websitegenelux.com